Frank I. Lin, M.D.
Dr. Lin is a board-certified physician in the fields of medical oncology and nuclear medicine. Dr. Lin's research interest is in the use of systemic, targeted radionuclides or conjugates as a treatment modality for cancer, and he is head of the Targeted Radionuclide Therapy Section of the Molecular Imaging Branch at NCI. Selected as a Lasker Clinical Research Scholar in 2016, Dr. Lin leads several pre-clinical investigations of radionuclide therapy agents as well as being the principal or associate investigator on a number of clinical trials at the NIH involving radionuclide therapy. Dr. Lin is particularly interested in the development and clinical translation of novel alpha particle and Auger electron-emitting radionuclides as targeted therapy for cancer.
1) targeted radionuclide therapy, 2) alpha particle-emitting radionuclides, 3) neuroendocrine tumors, 4) nuclear medicine, 5) positron emission tomography (PET), 6) theranostics
The vision of the Targeted Radionuclide Therapy Section is to accelerate the development and clinical translation of radionuclide therapy as a treatment modality for cancer. Dr. Lin is interested in and investigates a number of different radionuclides in both clinical and pre-clinical settings, but is particularly interested in the application of alpha particle and Auger electron-emitting agents. In addition to agent development and research, Dr. Lin is also involved in the promotion and advancement of the field of radionuclide therapy, including educational pursuits such as the training of future medical practitioners of this promising form of therapy.
Selected Recent Publications
Continuing Medical Education: Systemic Radionuclide Therapy of Pheochromocytoma/Paraganglioma.Journal of Nuclear Medicine and Molecular Imaging . [ Journal Article ]
Beyond Correlations, Sensitivities, and Specificities: Case Examples of the Evaluation of Advanced Imaging in Oncology Clinical Trials and Cancer Treatment.Acad Radiol. 2017. [ Journal Article ]
In vitro and in vivo comparison of 3,2-HOPO versus DFO-based chelation of zirconium-89 to the anti-mesothelin antibody anetumab.Cancer Biotherapy and Radiopharmaceuticals . 2017. [ Journal Article ]
Utility of 18F-fluoroestradiol (18F-FES) PET/CT imaging as a pharmacodynamic marker in patients with refractory estrogen receptor-positive solid tumors receiving Z-endoxifen therapy.Eur J Nucl Med Mol Imaging. 44(3): 500-508, 2017. [ Journal Article ]
Case Report: Primary Hypothyroidism Associated with Lutetium 177-DOTATATE Therapy for Metastatic Paraganglioma.Frontiers in Endocrinology-Cancer Endocrinology. Jan 12: 2021. [ Journal Article ]
Originally born in Taiwan, Dr. Lin immigrated with his family to the U.S. at a very young age and grew up in California. Dr. Lin's educational and professional pursuits has since taken him to many different parts of the United States. He completed his undergraduate work in biological sciences at Stanford University and has a Masters degree in medical informatics from the University of Utah. He went to medical school at the Medical College of Wisconsin and did his internal medicine and nuclear medicine residencies at Kaiser Permanente San Francisco and the University of California, Davis, respectively. After re-joining Stanford University for a PET/CT fellowship, Dr. Lin has worked at the NCI for the past 6 years in the Cancer Imaging Program in the Division of Cancer Treatment and Diagnosis. He was selected as a Lasker Clinical Research Scholar in 2016 and made the transition to intramural NCI as head of the newly created Targeted Radionuclide Therapy Section housed within the Molecular Imaging Branch headed by Dr. Peter Choyke.